Disease · MONDO_0006668

bacterial conjunctivitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. bacterial conjunctivitis. Diseases, record MONDO_0006668. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006668

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: bacterial conjunctivitis; Open Targets
Open Targets ID: MONDO_0006668; Open Targets
Other names: Bacteria caused conjunctival disease, Bacteria conjunctival disease, Conjunctivitis, Bacterial, Purulent conjunctivitis (disorder); Open Targets
Disease Ontology: DOID:9700; Disease Ontology
MeSH: D003234; MeSH
NCI Thesaurus: C53656; NCI Thesaurus
Highest stage of its drugs: Approval, for 5 of its 17 drugs, from DailyMed; Open Targets

Drugs17

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
GATIFLOXACIN	CHEMBL31	Small molecule	Approval	DailyMed	9	5	5	Drugs and targets
AZITHROMYCIN	CHEMBL529	Small molecule	Approval	DailyMed	5	4	3	Drugs and targets
LEVOFLOXACIN	CHEMBL5315124	Small molecule	Approval	DailyMed	3	2	2	Drugs and targets
MOXIFLOXACIN HYDROCHLORIDE	CHEMBL1200735	Small molecule	Approval	DailyMed	8	1	1	Drugs and targets
BESIFLOXACIN HYDROCHLORIDE	CHEMBL1201761	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
BESIFLOXACIN	CHEMBL1201760	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
MOXIFLOXACIN	CHEMBL32	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
POVIDONE-IODINE	CHEMBL1201724		Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
TOBRAMYCIN	CHEMBL1747	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 17

See all 17 drugs

Targets5

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
PTGS1	Cyclooxygenase	1	Cyclooxygenase inhibitor	Phase 2	https://conductscience.org/library/genes/5742	Drugs and targets
PTGS2	Cyclooxygenase	1	Cyclooxygenase inhibitor	Phase 2	https://conductscience.org/library/genes/5743	Drugs and targets
TOP2A	DNA topoisomerase II	1	DNA topoisomerase II inhibitor	Phase 3	https://conductscience.org/library/genes/7153	Drugs and targets
TOP2B	DNA topoisomerase II	1	DNA topoisomerase II inhibitor	Phase 3	https://conductscience.org/library/genes/7155	Drugs and targets

Trials27

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00759148	Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis	Phase 3	1,179	2011-03-22	Bacterial Conjunctivitis	MOXIFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT00348348	A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis	Phase 3	1,161	2009-08-13	Acute Bacterial Conjunctivitis	BESIFLOXACIN, MOXIFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT01573910	An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients	Phase 3	985	2015-05-12	Bacterial Conjunctivitis	MOXIFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT00347932	A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.	Phase 3	957	2009-08-13	Acute Bacterial Conjunctivitis	BESIFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT00518089	A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis	Phase 3	859	2011-11-30	Bacterial Conjunctivitis	GATIFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT03004924	Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo	Phase 3	753	2019-10-28	Bacterial Conjunctivitis	DEXAMETHASONE, POVIDONE-IODINE	Its record names the disease	ClinicalTrials.gov
NCT00105469	Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)	Phase 3	743	2011-10-27	Bacterial Conjunctivitis	AZITHROMYCIN, TOBRAMYCIN	Its record names the disease	ClinicalTrials.gov
NCT00105534	Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)	Phase 3	685	2011-10-27	Bacterial Conjunctivitis	AZITHROMYCIN	Its record names the disease	ClinicalTrials.gov
NCT00509873	A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis	Phase 3	578	2011-11-30	Bacterial Conjunctivitis	GATIFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT00972777	Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis	Phase 2/3	474	2012-03-29	Bacterial Conjunctivitis	BESIFLOXACIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 27

See all 27 trials

Comparisons in its trials42

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Moxifloxacin AF vs Vehicle: deaths from any cause	0 of 593	0 of 586	1,179	NCT00759148	Trial comparisons
Moxifloxacin AF vs Vehicle: serious adverse events	0 of 593	0 of 586	1,179	NCT00759148	Trial comparisons
Moxifloxacin Solution vs Besifloxacin Suspension: serious adverse events	1 of 579	1 of 582	1,161	NCT00348348	Trial comparisons
Moxifloxacin vs Ofloxacin: serious adverse events	1 of 489	0 of 493	982	NCT01573910	Trial comparisons
ISV-403 vs Vehicle: serious adverse events	1 of 442	1 of 432	874	NCT00347932	Trial comparisons
Gatifloxacin 0.5% Eye Drops vs Placebo Eye Drops: serious adverse events	2 of 429	0 of 427	856	NCT00518089	Trial comparisons
AzaSite vs Tobramycin: serious adverse events	0 of 365	0 of 378	743	NCT00105469	Trial comparisons
AzaSite vs Vehicle: serious adverse events	0 of 333	2 of 350	683	NCT00105534	Trial comparisons
Gatifloxacin 0.5% Eye Drops vs Placebo Eye Drops: serious adverse events	0 of 288	1 of 289	577	NCT00509873	Trial comparisons
Moxifloxacin Solution vs Besifloxacin Suspension: Clinical Resolution	167 of 281	147 of 252	533	NCT00348348	Trial comparisons

1 to 10 of 42

See all 42 comparisons in its trials

Papers from its trials12

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
21681652	RESULT	2	PubMed
32841261	DERIVED	3	PubMed
29602567	DERIVED	1	PubMed
25244402	DERIVED	1	PubMed
22644963	DERIVED	1	PubMed
22420526	DERIVED	1	PubMed
21397770	DERIVED	1	PubMed
20629472	DERIVED	3	PubMed
19393842	DERIVED	1	PubMed
19323612	DERIVED	1	PubMed

1 to 10 of 12

See all 12 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006668

GET https://conductscience.org/api/diseases/v1/MONDO_0006668/trials?page=2

API reference For AI assistants